123 related articles for article (PubMed ID: 14534702)
1. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study.
Rigatos SK; Tsavdaridis D; Athanasiadis A; Stathopoulos JG; Stathopoulos GP
Oncol Rep; 2003; 10(6):1817-9. PubMed ID: 14534702
[TBL] [Abstract][Full Text] [Related]
2. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
[TBL] [Abstract][Full Text] [Related]
3. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Rossi D; Baldelli AM; Casadei V; Fedeli SL; Alessandroni P; Catalano V; Giordani P; Ceccolini M; Graziano F; Catalano G
Anticancer Drugs; 2008 Aug; 19(7):733-7. PubMed ID: 18594216
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin plus paclitaxel in advanced breast cancer.
Dombernowsky P; Boesgaard M; Andersen E; Jensen BV
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-15-S17-8. PubMed ID: 9374086
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
[TBL] [Abstract][Full Text] [Related]
9. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Biganzoli L; Cufer T; Bruning P; Coleman RE; Duchateau L; Rapoport B; Nooij M; Delhaye F; Miles D; Sulkes A; Hamilton A; Piccart M
Cancer; 2003 Jan; 97(1):40-5. PubMed ID: 12491503
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
Martin M; Lluch A; Ojeda B; Barnabas A; Colomer R; Massuti B; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-26-S17-30. PubMed ID: 9374088
[TBL] [Abstract][Full Text] [Related]
13. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
Hortobagyi GN; Willey J; Rahman Z; Holmes FA; Theriault RL; Buzdar AU
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PubMed ID: 9374097
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and doxorubicin in metastatic breast cancer.
Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
18. Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.
Gianni L; Capri G
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S1-3. PubMed ID: 9071331
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
